What are the pediatric age tiers for local anesthetic dosing?

Pediatric local anesthetic dosing uses a 5-tier age system: Neonate ( = 96 months but < 18 years). Each tier applies a percentage reduction from the full child dose to account for immature hepatic metabolism and higher sensitivity to toxicity. Adolescents use pediatric adolescent fields, not adult fields — adult dosing begins at age 18+.

What is the safest local anesthetic for neonates?

The safest local anesthetic for neonates is 2-chloroprocaine (rank 1), an ester metabolized by plasma cholinesterase rather than hepatic CYP enzymes. Second-safest are levobupivacaine and tetracaine (rank 2) — levobupivacaine is the S-enantiomer of bupivacaine with less cardiotoxicity. Racemic bupivacaine (rank 5) should be avoided in neonates due to immature CYP3A4 metabolism and heightened cardiac sensitivity.

How do you calculate pediatric local anesthetic doses?

Pediatric local anesthetic doses are calculated using actual (total) body weight — never lean body weight. The formula is: max dose (mg) = max mg/kg for age tier × actual weight (kg). Each age tier applies a percentage of the full child/adolescent dose: neonates get 50%, young infants 70%, older infants 75-87.5% (agent-dependent), and children/adolescents get 100%. Always use the conservative (lower) end of the dose range as the fractional toxicity denominator.

What is the max dose of bupivacaine in a neonate?

The maximum dose of bupivacaine in a neonate (< 1 month) is 1-1.25 mg/kg without epinephrine and 1.5 mg/kg with epinephrine. This represents 50% of the full child dose (2-2.5 mg/kg). Bupivacaine is ranked 5th (least safe) for neonatal use due to immature CYP3A4 metabolism. Levobupivacaine at the same dosing is strongly preferred — it has the same potency with less cardiotoxicity.

Pediatric Local Anesthetic Dosing

Age-Tier Maximum Doses for All Agents — Neonate Through Adolescent

CLINICAL DECISION SUPPORT TOOL. This page is a reference aid for licensed healthcare professionals only. It does not replace clinical judgment. Pediatric patients — especially neonates — have fundamentally different pharmacokinetics. Always verify doses against current institutional protocols.

5-Tier Pediatric Age System

All pediatric local anesthetic doses in MaxLocal use a 5-tier age classification. Each tier applies a percentage reduction from the full child dose to account for hepatic enzyme immaturity, higher free-drug fractions (lower alpha-1 acid glycoprotein), and greater cardiac sensitivity.

Tier	Age Range	Typical Dose Fraction
Neonate	< 1 month	50%
Young Infant	1 – < 6 months	70%
Older Infant	6 – < 12 months	75% (87.5% for bupivacaine)
Child	1 – 7 years (12 – < 96 months)	100%
Adolescent	8+ years (≥ 96 months, < 18 years)	100%

Adolescent vs. Adult: Adolescents (8–17 years) use pediatric adolescent dose fields, NOT adult fields. Adult dosing begins at age 18+ (≥ 216 months). This distinction matters because adult weight-basis rules (lean body weight for BMI ≥ 30) and adult-specific dose ceilings do not apply to adolescents.

Maximum Doses Without Epinephrine (mg/kg)

Conservative (lower) and upper bounds shown. Percentages indicate the fraction of the full child dose applied to each tier.

Agent	Neonate < 1 mo	Young Infant 1 – < 6 mo	Older Infant 6 – < 12 mo	Child 1 – 7 yr	Adolescent 8 – 17 yr
Lidocaine	2.25–2.5 (50%)	3.15–3.5 (70%)	3.375–3.75 (75%)	4.5–5 (100%)	4.5–5 (100%)
Bupivacaine	1–1.25 (50%)	1.4–1.75 (70%)	1.75–2.19 (87.5%)	2–2.5 (100%)	2–2.5 (100%)
Ropivacaine	1.5 (50%)	2.1 (70%)	2.25 (75%)	3 (100%)	3 (100%)
Mepivacaine	2.5 (50%)	3.5 (70%)	3.75 (75%)	5–7 (100%)	5–7 (100%)
2-Chloroprocaine	8–10 (80%)	— (70%)	— (75%)	11 (100%)	11 (100%)

Reading dose ranges: Where two numbers appear (e.g., 2.25–2.5), the lower value is the conservative maximum used as the fractional toxicity denominator. Doses between lower and upper trigger a soft warning. Doses above upper trigger a hard block.

Maximum Doses With Epinephrine (mg/kg)

Epinephrine (typically 1:200,000) slows systemic absorption, allowing higher local tissue concentrations before toxic plasma levels are reached.

Agent	Neonate < 1 mo	Young Infant 1 – < 6 mo	Older Infant 6 – < 12 mo	Child 1 – 7 yr	Adolescent 8 – 17 yr
Lidocaine	3.5 (50%)	4.9 (70%)	5.25 (75%)	7 (100%)	7 (100%)
Bupivacaine	1.5 (50%)	2.1 (70%)	2.625 (87.5%)	3 (100%)	3 (100%)
Ropivacaine	1.75 (50%)	2.45 (70%)	2.625 (75%)	3 (capped)	3 (capped)
Mepivacaine	3.5 (50%)	4.9 (70%)	5.25 (75%)	7 (100%)	7 (100%)
2-Chloroprocaine	11.2 (80%)	— (70%)	— (75%)	14 (100%)	14 (100%)

Ropivacaine "capped": Ropivacaine with epinephrine in children and adolescents is capped at 3 mg/kg — the same as without epinephrine. Unlike lidocaine and mepivacaine, epinephrine provides minimal additional dose margin for ropivacaine due to its intrinsic vasoconstrictive properties.

Tetracaine

Tetracaine is an ester-type local anesthetic primarily used for spinal anesthesia in pediatrics. As an ester, it is metabolized by plasma cholinesterase — not hepatic CYP enzymes — making it relatively safe in neonates.

Parameter	Value
Max dose (no epinephrine only)	1.5 mg/kg
Type	Ester
Neonatal safety rank	2 (second-safest)
Primary use	Spinal anesthesia (neonatal and infant)

Levobupivacaine

Levobupivacaine is the S-enantiomer of bupivacaine. It has equivalent analgesic potency but significantly less cardiotoxicity — making it the preferred long-acting amide for neonates when bupivacaine would otherwise be considered.

Parameter	Value
Dosing	Same as bupivacaine (all age tiers)
Type	Amide (S-enantiomer)
Neonatal safety rank	2 (preferred over racemic bupivacaine)
Key advantage	Less cardiotoxic than racemic bupivacaine at equi-effective doses
Clinical note	If a long-acting amide is needed in a neonate, choose levobupivacaine over bupivacaine

Availability note: Levobupivacaine (Chirocaine) is not available in the United States. It is available in Europe, the UK, Australia, and many other markets. Where unavailable, ropivacaine is the preferred reduced-cardiotoxicity alternative.

Exparel (Liposomal Bupivacaine)

Exparel is a liposomal formulation of bupivacaine that provides extended-release analgesia lasting up to 72 hours. It has specific pediatric age restrictions.

Parameter	Value
Max dose	4 mg/kg (max 266 mg absolute)
Minimum age	6 years
Under 6 years	NOT APPROVED — do not use
Fractional toxicity	100% FT coupling (FDA label: additive toxicity with plain bupivacaine)

AGE RESTRICTION: Exparel is not approved for patients under 6 years of age. Do not extrapolate dosing to younger children. The liposomal formulation has not been studied in infants or neonates.

Neonatal Safety Ranking

When choosing a local anesthetic for neonates (< 1 month), agent selection matters as much as dose. The following ranking reflects the balance of hepatic enzyme immaturity, protein binding, and intrinsic cardiotoxicity.

Rank	Agent	Rationale
1 (Safest)	2-Chloroprocaine	Ester — metabolized by plasma cholinesterase, not hepatic CYP. Rapid hydrolysis, very short half-life. Ideal for neonatal neuraxial use.
2	Levobupivacaine	S-enantiomer of bupivacaine. Same potency, significantly less cardiotoxic. Preferred long-acting amide for neonates.
2	Tetracaine	Ester — no hepatic CYP dependence. Long track record in neonatal spinal anesthesia.
5 (Avoid)	Bupivacaine	Racemic mixture with higher cardiotoxicity. Metabolized by CYP3A4 (immature in neonates). Higher risk of fatal cardiac arrest at lower relative doses.

AVOID BUPIVACAINE IN NEONATES. Racemic bupivacaine has the highest cardiotoxicity risk among commonly used local anesthetics. Neonatal CYP3A4 activity is approximately 30–50% of adult levels, prolonging drug half-life and increasing accumulation risk. Use chloroprocaine, levobupivacaine, or ropivacaine instead.

CYP Enzyme Maturation

Amide local anesthetics depend on hepatic cytochrome P450 enzymes for metabolism. The dose reductions in younger tiers directly reflect the immaturity of these enzyme systems.

Enzyme	Maturation Age	Agents Affected
CYP3A4	Matures at 9–12 months	Bupivacaine, levobupivacaine, ropivacaine
CYP1A2	Matures at 7–8 years	Lidocaine, mepivacaine

Clinical implication: CYP1A2 matures much later than CYP3A4. This is why lidocaine and mepivacaine dose reductions persist through the older infant tier — their primary metabolic pathway does not reach adult capacity until age 7–8 years. Ester agents (chloroprocaine, tetracaine) bypass hepatic CYP entirely, which is why they are preferred in the youngest patients.

Weight Basis for Pediatric Dosing

Pediatric patients always use actual (total) body weight. The lean body weight adjustment used in obese adults (BMI ≥ 30) does NOT apply to pediatric patients. All mg/kg calculations for patients under 18 years use the actual measured weight.

Population	Weight Basis
All pediatric patients (< 18 years)	Actual body weight (always)
Adult, BMI < 30	Total body weight
Adult, BMI ≥ 30	Lean body weight (Janmahasatian 2005)

Neonatal Cardiovascular Collapse Warning

CRITICAL — ABSENT CNS PRODROME: Neonates and infants under 6 months may present with sudden cardiovascular collapse without the typical CNS warning signs (metallic taste, tinnitus, perioral numbness, seizures) that precede toxicity in older children and adults. The first sign of toxicity may be bradycardia, hypotension, or cardiac arrest.

This occurs because:

Immature blood-brain barrier allows simultaneous CNS and cardiovascular toxicity
Higher cardiac output relative to body mass delivers drug to the heart faster
Lower alpha-1 acid glycoprotein levels increase free (unbound) drug fraction
Immature cardiac sodium channels are more susceptible to blockade

Always have lipid emulsion (Intralipid 20%) immediately available when performing regional anesthesia in neonates or young infants. See the LAST Protocol page for treatment dosing.

Calculate Pediatric Doses with MaxLocal

Age-tiered dosing, fractional toxicity tracking, neonatal safety warnings, and instant LAST protocol access — all offline, no patient data stored.

Get MaxLocal on Google Play

Learn more at max-local.app

Related Dosing Guides

References

Suresh S, Schaldenbrand K, Engbretsen B, Palac H. Pediatric local anesthetic dosing: evidence-based recommendations. Reg Anesth Pain Med. 2014;39(5):387-397.
Lerman J, Strong HA, LeDez KM, et al. Effects of age on the serum concentration of alpha-1 acid glycoprotein and the binding of lidocaine in pediatric patients. Clin Pharmacol Ther. 1989;46(2):219-225.
Berde CB. Toxicity of local anesthetics in infants and children. J Pediatr. 1993;122(5 Pt 2):S14-20.
Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4):169-175.
Neal JM, Barrington MJ, Fettiplace MR, et al. The Third ASRA Practice Advisory on Local Anesthetic Systemic Toxicity. Reg Anesth Pain Med. 2020;45(4):247-253.
Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004;29(6):564-575.
Pacifica Group. EXPAREL (bupivacaine liposome injectable suspension) prescribing information. 2023.

Clinical Decision Support Tool. This page is intended as a reference aid for licensed healthcare professionals only. It does not replace clinical judgment. Always verify information against current guidelines and institutional protocols. Pediatric local anesthetic dosing requires careful consideration of age, weight, comorbidities, and injection site.